903 related articles for article (PubMed ID: 25605056)
1. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
2. [Current issues regarding companion diagnostics and future prospects].
Tazawa Y
Rinsho Byori; 2014 Apr; 62(4):381-9. PubMed ID: 25022068
[TBL] [Abstract][Full Text] [Related]
3. [The current issues on development and clinical use of companion diagnostics and prospects of personalized medicine for the future].
Tazawa Y
Yakugaku Zasshi; 2014; 134(4):491-8. PubMed ID: 24694808
[TBL] [Abstract][Full Text] [Related]
4. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
5. Laboratory-Developed Tests: A Legislative and Regulatory Review.
Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
[TBL] [Abstract][Full Text] [Related]
6. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European
Vanstapel FJLA; Orth M; Streichert T; Capoluongo ED; Oosterhuis WP; Çubukçu HC; Bernabeu-Andreu FA; Thelen M; Jacobs LHJ; Linko S; Bhattoa HP; Bossuyt PMM; Meško Brguljan P; Boursier G; Cobbaert CM; Neumaier M
Clin Chem Lab Med; 2023 Mar; 61(4):608-626. PubMed ID: 36716120
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
Thompson BM; Scott BI; Boiani JA
Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
[TBL] [Abstract][Full Text] [Related]
8. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
9. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
Nobori T; Nomura F
Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
[TBL] [Abstract][Full Text] [Related]
10. FDA's proposed rule for the regulation of laboratory-developed tests.
Miller MB; Watts ML; Samuel L
J Clin Microbiol; 2024 Feb; 62(2):e0148823. PubMed ID: 38206042
[TBL] [Abstract][Full Text] [Related]
11. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
12. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.
Kim AS; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Moncur JT
JAMA Oncol; 2018 Jun; 4(6):838-841. PubMed ID: 29242895
[TBL] [Abstract][Full Text] [Related]
14. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
15. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
17. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
18. Companion Diagnostics and Molecular Imaging.
Puranik AD; Kulkarni HR; Baum RP
Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
[TBL] [Abstract][Full Text] [Related]
19. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
20. Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).
Spitzenberger F; Patel J; Gebuhr I; Kruttwig K; Safi A; Meisel C
Ther Innov Regul Sci; 2022 Jan; 56(1):47-64. PubMed ID: 34291407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
